Clinical trials

  • Mitomycin C for Non-muscle invasive bladder cancer
  • Pembrolizumab for Mucosal melanoma|Melanoma
  • MITOMYCIN for Peritoneal metastases of colorectal cancer
  • ATUMELNANT for Classic congenital adrenal hyperplasia|Congenital adrenal hyperplasia
  • NATALIZUMAB for Relapsing-remitting multiple sclerosis | Multiple sclerosis
  • BP1.7881 for Eosinophilic esophagitis
  • Onasemnogene abeparvovec for Spinal muscular atrophy
  • 5,8-DICHLORO-2-[(4-METHOXY-6-METHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL]-7-[(R)-METHOXY(OXETAN-3-YL)METHYL]-3,4-DIHYDROISOQUINOLIN-1(2H)-ONE for Metastatic castration-sensitive prostate cancer
  • Gallium (68Ga) tezatabep matraxetan for Breast cancer|Metastatic breast cancer
  • HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE PARTICLES PRODUCED IN YEAST CELLS (SACCHAROMYCES CEREVISIAE CANADE 3C-5 (STRAIN 1895)) BY RDNA; HUMAN PAPILLOMAVIRUS TYPE 33 L1 PROTEIN - ADSORBED ... (and other HPV L1 proteins for types 45, 52, 58, 11, 16, 18, 6) (as listed in product dictionary) for High-grade cervical intraepithelial lesions
  • DURVALUMAB for Resectable gastric cancer | Resectable gastroesophageal junction cancer (MSI-high)
  • TELITACICEPT for Systemic lupus erythematosus (moderately to severely active)